Eli Lilly: Strong Stock Surge after ATTAIN-2 Results

Eli Lilly's stock (NYSE: LLY) surged significantly on Tuesday, gaining up to 5.9% during the day. The catalyst was the release of compelling data from the oral weight loss pill Orforglipron from the Phase 3 study ATTAIN-2. Following the rather subdued market feedback on the previous ATTAIN-1 study, the stock experienced a clear rebound – accompanied by growing confidence on Wall Street. Impressive efficacy The ATTAIN-2 study shows that Orforglipron resulted in an average weight loss of 10.5% (22.9 pounds) over 72 weeks in overweight patients...